CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
GlaxoSmithKline will work to develop an experimental HIV vaccine in collaboration with a nonprofit group, in the first such public-private HIV vaccine partnership involving a major company. Jean Stephenne, head of GSK Biologicals, the vaccines arm of Europe's biggest drugmaker, said on Tuesday the deal with the International AIDS Vaccine Initiative would speed research into a novel way of stopping the deadly virus. IAVI will provide expertise and funding for the research, and the two organizations will form a joint research and development team, with GSK committed to making any successful vaccine available in developing countries at affordable prices. Such public-private partnerships are being used increasingly to tackle diseases, including malaria and tuberculosis, which occur primarily in poor countries in which Western pharmaceutical companies stand little chance of making money. GSK's new vaccine approach uses a chimpanzee virus, known as an adenovirus, which has been engineered to be noninfectious, to carry HIV proteins into cells and trigger an immune response. The company believes this primate virus, using technology derived from the University of Pennsylvania, should be more effective than a human one, since people will not have preexisting resistance to it, which could stop human viruses from acting as transporters of the vaccine. But it will be a long time before the fruits of the collaboration are seen, since the first clinical trials of the technology are a few years away. Industry analysts said this suggests that a commercially available vaccine is unlikely for at least a decade, even if everything goes according to plan. Merck earlier this year started a Phase II trial on vaccine based on a weakened human adenovirus, similar to one that causes the common cold. Other companies developing HIV vaccines include Sanofi-Aventis and Chiron. All told, more than 30 vaccine candidates are now in clinical trials around the world, but scientists are not confident that any of them will be really effective at defeating HIV. The virus is a particularly difficult to tackle because it attacks the immune system and mutates so frequently. (Reuters)
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Nancy Pelosi endorses Kamala Harris for president
July 22 2024 4:07 PM
Charli XCX declares Kamala Harris IS brat & our next President's campaign agrees
July 22 2024 3:08 PM
Pete Buttigieg roasts JD Vance and his gay tech bro billionaire
July 22 2024 1:42 PM
The AIDs pandemic can be ended by 2030, but governments must act: report
July 22 2024 1:01 PM
Conservatives' first attack on Kamala Harris: Pronouns and accessibility?
July 22 2024 12:45 PM
Advancing equality during Disability Pride Month
July 22 2024 11:30 AM